Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,707 matching trials from the live ClinicalTrials.gov search.
Conditions
Pancreatectomy
Interventions
Lidocaine, Placebo D5W
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ABBV-969
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Conditions
Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia
Interventions
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2Phase 3 Interventional Results available

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
Conditions
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Leukemia, Lymphoma, Multiple Myeloma, MDS, Myelodysplastic/Myeloproliferative Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Duarte, California
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Solid Tumors
Interventions
ABBV-303, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 7 more
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 in Healthy Adults

NCT05059977
Conditions
Healthy Volunteers
Interventions
TAK-881
Biological
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hialeah, Florida
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma
Interventions
Natural Killer Cells, Temozolomide, Irinotecan, Dinutuximab, Sargramostim
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 29 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Conditions
Hematological Malignancies
Interventions
Naive T Cell Depleted Donor Lymphocyte Infusion
Biological
Lead sponsor
Mitchell Horwitz, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia, CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), Acute Lymphoblastic Leukemia, AML (Acute Myelogenous Leukemia)
Interventions
MVST, MVSTr
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Liver Cancer
Interventions
TriSalus™ TriNav™Infusion System, Angiogram, Y90-radioembolization procedure
Device · Diagnostic Test · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, conventional surgery
Biological · Procedure
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 1 more
Conditions
Insomnia, Sleep Disorder, Dyssomnia
Interventions
propofol injectable emulsion
Drug
Lead sponsor
Life Extension Foundation Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Metastatic Melanoma
Interventions
tasisulam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Lakeland, Florida + 5 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Secondary Myelofibrosis
Interventions
peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation (TBI)
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions
ALD-401, Sham Procedure
Biological · Procedure
Lead sponsor
Aldagen
Industry
Eligibility
30 Years to 83 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more
Conditions
Hepatic Metastases, Colon Cancer, Rectal Cancer
Interventions
Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Conditions
Leukemia, Lymphoma, Lymphoma, B-Cell
Interventions
CAR T-Cell Infusion
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

7 Day Continuous Parathyroid Hormone IV Infusion

NCT00377312
Conditions
Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
Interventions
Parathyroid Hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania